Tempest Therapeutics stockholders approved the potential issuance of 20% or more of its common stock to Lincoln Park Capital Fund, LLC, and the exercise of warrants generating up to approximately 6.4 million shares. The company also ratified Ernst & Young LLP as its auditor and elected directors John David Yee and William Drake Richey. Tempest Therapeutics operates in the biotechnology industry.
